Publicação

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Detalhes bibliográficos
Resumo:	This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.
Autores principais:	Michelsen, Brigitte
Outros Autores:	Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Ørnbjerg, Lykke Midtbøll; Zavada, Jakub; Glintborg, Bente; MacDonald, Alan; Laas, Karin; Nordström, Dan; Gudbjornsson, Bjorn; Iannone, Florenzo; Hellmand, Pasoon; Kvien, Tore Kristian; Rodrigues, Ana Maria; Maria Rodrigues, Ana; Codreanu, Catalin; Rotar, Ziga; Castrejón Fernández, Isabel; Wallman, Johan Karlsson; Vencovsky, Jiri; Loft, Anne Gitte; Heddle, Maureen; Vorobjov, Sigrid; Hokkanen, Anna Mari; Gröndal, Gerdur; Sebastiani, Marco; van de Sande, Marleen; Kristianslund, Eirik Klami; Santos, Maria José; Mogosan, Corina; Tomsic, Matija; Díaz-González, Federico; Di Giuseppe, Daniela; Hetland, Merete Lund
Assunto:	Axial spondyloarthritis Health policy Psoriatic arthritis Treatment recommendations Internal Medicine Oncology Health Policy SDG 3 - Good Health and Well-being
Ano:	2023
País:	Portugal
Tipo de documento:	recensão
Tipo de acesso:	acesso aberto
Instituição associada:	Universidade Nova de Lisboa
Idioma:	inglês
Origem:	Repositório Institucional da UNL

Descrição
Resumo:	This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.